IFNG and candidiasis: Recently, the use of the Jak kinase inhibitor Ruxolitinib was demonstrated to correct STAT1 hyperphosphorylation and ameliorate Candida infection (5, 6); therefore, we tested and demonstrated inhibition of STAT1 phosphorylation by Ruxolitinib in EBV-LCLs from our patient upon stimulation with IFN-α and IFN-γ (Figure 3B).